Keeping Track: US FDA Approves Novartis’ Scemblix; Lilly Submits Tirzepatide, Withdraws Tanezumab

 
• By Bridget Silverman

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers